Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
NEW YORK, NY, September 10, 2025 – Royalty Pharma plc today announced the release of a biopharma royalty market study conducted by Deloitte.
Ad-hoc
Royalty Pharma published press releases by date and/or category
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, NY, May 16, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”).
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
NEW YORK, NY, May 12, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma’s 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
NEW YORK, NY, July 24, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital.
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
NEW YORK, NY, June 3, 2024 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”)
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
NEW YORK, NY, September 21, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee.
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
NEW YORK, NY, March 1, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman.
Royalty Pharma Announces Expansion of Senior Leadership Team
NEW YORK, NY, December 15, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team . This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced
Royalty Pharma Announces Expansion of Leadership Team
NEW YORK, NY, October 12, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team . Art McGivern has joined Royalty Pharma as Executive Vice President, Investments & General Counsel and George Lloyd has been promoted to Executive Vice President, Investments & Chief Legal Officer.
Royalty Pharma Announces Strategic Alliance with MSCI to Launch Life Sciences Indexes
NEW YORK, NY, April 21, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, to expand MSCI’s thematic index suite with the launch of new indexes
